Acta Pharmaceutica Sinica B 2025;15(11):6091−6092

Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

www.elsevier.com/locate/apsb
www.sciencedirect.com

CORRECTION

Author correction to "Structurally defined tandem-responsive nanoassemblies composed of dipeptide-based photosensitive derivatives and hypoxia-activated camptothecin prodrugs against primary and metastatic breast tumors" [Acta Pharm Sin B 12 (2022) 952−966]

Mengchi Sun[a], Hailun Jiang[b], Tian Liu[a], Xiao Tan[a], Qikun Jiang[a], Bingjun Sun[b], Yulong Zheng[c], Gang Wang[d], Yang Wang[d], Maosheng Cheng[b], Zhonggui He[a,*], Jin Sun[a,*]

[a]*Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China*
[b]*Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, Ministry of Education, Shenyang 110016, China*
[c]*School of Materials Science and Engineering, Ocean University of China, Qingdao 266100, China*
[d]*College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China*

In the originally published version of this article, the authors identified inadvertent errors in the preparation of Fig. 7A and B. During assembly of the figure, incorrect images from the same batch of raw data were mistakenly selected and duplicated across two separate studies. The figure has now been replaced with the correct images sourced from the same original dataset. The original data supporting these corrections have been provided to the Editorial Office. For access to the original data, please contact the corresponding authors.

The authors sincerely apologize for any inconvenience or misunderstanding that may have resulted from this error.

The corrected version of the Figure is presented below.

DOI of original article: https://doi.org/10.1016/j.apsb.2021.08.008.
*Corresponding authors.
E-mail addresses: hezhonggui@vip.163.com (Zhonggui He), sunjin@syphu.edu.cn (Jin Sun).
Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

https://doi.org/10.1016/j.apsb.2025.09.034



Figure 7 *In vivo* biodistribution of DiR-labeled co-nanoassemblies. (A) *In vivo* fluorescence imaging of 4T1 tumor-bearing mice at 3, 6, 9, 12, and 24 h after i.v. injection of free DiR or DiR-labeled co-nanoassemblies (DiR 2 mg/kg). Arrows refer to the tumor regions. (B) *Ex vivo* fluorescence imaging of excised tumors and major organs at 9 h after i.v. injection from top to bottom (1, heart; 2, liver; 3, spleen; 4, lung; 5, kidney; 6, tumor).